Promotie onderzoek

Het onderzoek richt zich op de invloed van een CDSS op de medicatieveiligheid en de rol van de ziekenhuisapotheker. We onderzoeken oa de invloed van het CDSS op het aantal en soort consulten door ziekenhuisapotheker, de invloed van het CDSS op medicatiefouten bij levercirrhose patienten en de mogelijkheid om CDSS in te zetten bij intoxicaties.

New medicines are evaluated by registration authorities in order to assess their benefit-risk-balance. However, not every new medicine has to have an added therapeutic value compared to already available medicines. The real clinical relevance of new medicine is therefore sometimes unclear. In this research project, we want to investigate the views of healthcare professionals (HCPs) on clinical relevance of new medicines in primary care. We will discuss healthcare professionals’ views on clinical relevance of new COPD and T2DM medicines and also describe the reasons for prescribing new medicines, which is often not in line with guideline recommendations. Finally, we want to investigate how healthcare professionals assess the clinical relevance of medicines that obtained market access in the last years, and to investigate which pharmaceutical gaps (in other words: which diseases cannot be properly treated and would demand new therapies) HCPs identify in their daily practice. 

The aim of this PhD is to study the role of drug metabolism in adverse drug reactions (ADRs), an area which is not often taken into account in pharmacovigilance. The role of metabolites in ADRs is studied by focusing on (but not limiting to) a number of  therapeutic drug groups.

Onderzoeksprojekt over de mogelijkheden die de beweging naar continue
farmaceutische patiëntenzorg helpen mogelijk te maken dan wel te versnellen.

European funded project to reduce the inappropriate use of antibiotics in common infectious diseases by implementing EU guidelines for the prudent use of antimicrobials in human health. Implementing the Audit Project Odense (APO) methodology in community pharmacies in 5 European countries (France, Spain, Lithuania, Poland and Greece).

Drug utilization of antihypertensives in the Baltic countries.